Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-05564-z |
| id |
doaj-daa72fc740814394b7993401524f3f72 |
|---|---|
| record_format |
Article |
| spelling |
doaj-daa72fc740814394b7993401524f3f722021-05-11T10:22:50ZengNature Publishing GroupNature Communications2041-17232018-09-019111610.1038/s41467-018-05564-zMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova0Monique Topp1Ksenija Nesic2Elizabeth Lieschke3Gwo-Yaw Ho4Maria I. Harrell5Giada V. Zapparoli6Alison Hadley7Robert Holian8Emma Boehm9Valerie Heong10Elaine Sanij11Richard B. Pearson12John J. Krais13Neil Johnson14Orla McNally15Sumitra Ananda16Kathryn Alsop17Karla J. Hutt18Scott H. Kaufmann19Kevin K. Lin20Thomas C. Harding21Nadia Traficante22Australian Ovarian Cancer Study (AOCS)Anna deFazio23Iain A. McNeish24David D. Bowtell25Elizabeth M. Swisher26Alexander Dobrovic27Matthew J. Wakefield28Clare L. Scott29The Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchDepartment of Obstetrics and Gynecology, University of WashingtonOlivia Newton-John Cancer Research InstituteThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchResearch Division, Peter MacCallum Cancer CentreResearch Division, Peter MacCallum Cancer CentreFox Chase Cancer CentreFox Chase Cancer CentreRoyal Women’s HospitalRoyal Women’s HospitalResearch Division, Peter MacCallum Cancer CentreDepartment of Medicine and Health Sciences, Monash UniversityDepartments of Oncology and Molecular Pharmacology, Mayo ClinicClovis OncologyClovis OncologyResearch Division, Peter MacCallum Cancer CentreCentre for Cancer Research, The Westmead Institute for Medical Research, Sydney Medical School, The University of Sydney and Department of Gynaecological Oncology, Westmead HospitalDivision of Cancer, Department of Surgery and Cancer, Imperial College London, KensingtonResearch Division, Peter MacCallum Cancer CentreDepartment of Obstetrics and Gynecology, University of WashingtonOlivia Newton-John Cancer Research InstituteThe Walter and Eliza Hall Institute of Medical ResearchThe Walter and Eliza Hall Institute of Medical ResearchAround 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC.https://doi.org/10.1038/s41467-018-05564-z |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Olga Kondrashova Monique Topp Ksenija Nesic Elizabeth Lieschke Gwo-Yaw Ho Maria I. Harrell Giada V. Zapparoli Alison Hadley Robert Holian Emma Boehm Valerie Heong Elaine Sanij Richard B. Pearson John J. Krais Neil Johnson Orla McNally Sumitra Ananda Kathryn Alsop Karla J. Hutt Scott H. Kaufmann Kevin K. Lin Thomas C. Harding Nadia Traficante Australian Ovarian Cancer Study (AOCS) Anna deFazio Iain A. McNeish David D. Bowtell Elizabeth M. Swisher Alexander Dobrovic Matthew J. Wakefield Clare L. Scott |
| spellingShingle |
Olga Kondrashova Monique Topp Ksenija Nesic Elizabeth Lieschke Gwo-Yaw Ho Maria I. Harrell Giada V. Zapparoli Alison Hadley Robert Holian Emma Boehm Valerie Heong Elaine Sanij Richard B. Pearson John J. Krais Neil Johnson Orla McNally Sumitra Ananda Kathryn Alsop Karla J. Hutt Scott H. Kaufmann Kevin K. Lin Thomas C. Harding Nadia Traficante Australian Ovarian Cancer Study (AOCS) Anna deFazio Iain A. McNeish David D. Bowtell Elizabeth M. Swisher Alexander Dobrovic Matthew J. Wakefield Clare L. Scott Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma Nature Communications |
| author_facet |
Olga Kondrashova Monique Topp Ksenija Nesic Elizabeth Lieschke Gwo-Yaw Ho Maria I. Harrell Giada V. Zapparoli Alison Hadley Robert Holian Emma Boehm Valerie Heong Elaine Sanij Richard B. Pearson John J. Krais Neil Johnson Orla McNally Sumitra Ananda Kathryn Alsop Karla J. Hutt Scott H. Kaufmann Kevin K. Lin Thomas C. Harding Nadia Traficante Australian Ovarian Cancer Study (AOCS) Anna deFazio Iain A. McNeish David D. Bowtell Elizabeth M. Swisher Alexander Dobrovic Matthew J. Wakefield Clare L. Scott |
| author_sort |
Olga Kondrashova |
| title |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma |
| title_short |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma |
| title_full |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma |
| title_fullStr |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma |
| title_full_unstemmed |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma |
| title_sort |
methylation of all brca1 copies predicts response to the parp inhibitor rucaparib in ovarian carcinoma |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-09-01 |
| description |
Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC. |
| url |
https://doi.org/10.1038/s41467-018-05564-z |
| work_keys_str_mv |
AT olgakondrashova methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT moniquetopp methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT ksenijanesic methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT elizabethlieschke methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT gwoyawho methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT mariaiharrell methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT giadavzapparoli methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT alisonhadley methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT robertholian methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT emmaboehm methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT valerieheong methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT elainesanij methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT richardbpearson methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT johnjkrais methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT neiljohnson methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT orlamcnally methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT sumitraananda methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT kathrynalsop methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT karlajhutt methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT scotthkaufmann methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT kevinklin methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT thomascharding methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT nadiatraficante methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT australianovariancancerstudyaocs methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT annadefazio methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT iainamcneish methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT daviddbowtell methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT elizabethmswisher methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT alexanderdobrovic methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT matthewjwakefield methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma AT clarelscott methylationofallbrca1copiespredictsresponsetotheparpinhibitorrucaparibinovariancarcinoma |
| _version_ |
1721448330182000640 |